Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (11-20 of 316) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2019
Detection of <i>NRG1</i> Fusions in Solid Tumors: Rare Gold?Anastasios Dimou, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Authors' ReplyD Ross Camidge, Rafal Dziadziuszko,
The Lancet. Oncology|October 8, 2019
Untapped potential: recognising CNS opportunities in early oncology drug developmentTejas Patil, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2024
Lung Cancer Oncogene-Directed Therapy, Fertility, and PregnancyEmily Simons, D Ross Camidge
JACC. Cardiooncology|March 6, 2023
Significance of Alectinib-Induced Bradycardia: Rhythm and Reversibility Matter More Than RateLavanya Kondapalli, D Ross Camidge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung CancerD Ross Camidge, Kurtis D Davies
Annals of Translational Medicine|June 2, 2017
AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?Terry L Ng, D Ross Camidge
The Lancet. Respiratory Medicine|April 20, 2018
Targeting ALK in inflammatory myofibroblastic tumoursVictor M Villalobos, D Ross Camidge
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Antibody drug conjugates in thoracic malignanciesJose M Pacheco, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 16, 2012
Have mutation, will travel: utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncologyHoward Jack West, D Ross Camidge
Pageof 32

Showing results (11-20 of 316) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2019
Detection of <i>NRG1</i> Fusions in Solid Tumors: Rare Gold?Anastasios Dimou, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Authors' ReplyD Ross Camidge, Rafal Dziadziuszko,
The Lancet. Oncology|October 8, 2019
Untapped potential: recognising CNS opportunities in early oncology drug developmentTejas Patil, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2024
Lung Cancer Oncogene-Directed Therapy, Fertility, and PregnancyEmily Simons, D Ross Camidge
JACC. Cardiooncology|March 6, 2023
Significance of Alectinib-Induced Bradycardia: Rhythm and Reversibility Matter More Than RateLavanya Kondapalli, D Ross Camidge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung CancerD Ross Camidge, Kurtis D Davies
Annals of Translational Medicine|June 2, 2017
AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?Terry L Ng, D Ross Camidge
The Lancet. Respiratory Medicine|April 20, 2018
Targeting ALK in inflammatory myofibroblastic tumoursVictor M Villalobos, D Ross Camidge
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Antibody drug conjugates in thoracic malignanciesJose M Pacheco, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 16, 2012
Have mutation, will travel: utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncologyHoward Jack West, D Ross Camidge
Pageof 32